Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-29
1999-10-19
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 11, A61K 31335
Patent
active
059689722
ABSTRACT:
A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent, (e.g., cyclosporin A, cyclosporin D, ketoconazole or captopril). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.
REFERENCES:
patent: 5114951 (1992-05-01), King
patent: 5118493 (1992-06-01), Kelley et al.
patent: 5124330 (1992-06-01), King
patent: 5124338 (1992-06-01), King
patent: 5124339 (1992-06-01), King
patent: 5166207 (1992-11-01), Smith
patent: 5208238 (1993-05-01), King
patent: 5300282 (1994-04-01), King
patent: 5346897 (1994-09-01), King
patent: 5364843 (1994-11-01), King
patent: 5387685 (1995-02-01), Powell et al.
patent: 5395610 (1995-03-01), King
patent: 5416091 (1995-05-01), King
Joel, et al., Cancer Chemother. Pharmac., vol. 37, pp. 125-133 (1995).
Schinkel, et al., J. Clin. Invest., vol. 96, pp. 1698-1705 (1995).
Scheffer, et al., Nature Medicine, vol. 1, No. 6, pp. 578-582 (1995).
Lum, et al., Drug Resistance in Clin. Onc. and Hematology, vol. 9, No. 2, pp. 319-336 (1995).
Fracasso, et al., Proc. of ASCO, vol. 14, Abstract 1585, p. 486 (1995).
Bissery, Euro. J. Cancer, vol. 31A, Sup. 4, pp. S1-S6 (1995).
Leu, et al., Cancer Chem. Pharmac., vol. 35, No. 5, pp. 432-436 (1995).
Keogh, et al., N.E. J. Med., vol. 333, No. 10, pp. 628-633 (1995).
Leveque, et al., Anticancer Res. vol. 15, pp. 331-336 (1995).
Montaseri, et al., Pharm. Res., vol. 12, No. 9, p. S-429, Abstract PPDM 8411 (1995).
Pouvelle, et al., J. Clin. Invest., vol. 94, pp. 413-417 (1994).
Schinkel, et al., Cell, vol. 77, pp. 491-502 (1994).
Fisher, et al., Proc. of ASCO, vol. 13, Abstract 369, p. 144 (1994).
Siegsmund, et al., J. Urol., vol. 151, pp. 485-491 (1994).
Cresteil, et al., Cancer Res., vol. 54, pp. 386-392 (1994).
Bartlett, et al., J. Clin. Onc., vol. 12, No. 4, pp. 835-842 (1994).
Sikic, et al., Anticancer Drug Resistance: Adv. Molec. Clin. Res., pp. 149-165 (1994).
Kumar, et al., J. of Pharmac. and Exp. Therapeutics, vol. 268, No. 3, pp. 1160-1165 (1994).
Lepage, et al., Current Op. in Neph. and Hypert., vol. 2, pp. 735-743 (1993).
Lum, et al., J. Clin. Onc., vol. 10, No. 10, pp. 1635-1642 (1992).
Loehrer, Seminars in Onc., vol. 18, No. 6, Sup. 14, pp. 48-52 (1992).
Keller, et al., Int. J. Cancer, vol. 51, pp. 433-438 (1992).
Broder Samuel
Duchin Kenneth L.
Selim Sami
Baker Norton Pharmaceuticals, Inc.
Raymond Richard L.
LandOfFree
Method for increasing the oral bioactivity of pharmaceutical age does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing the oral bioactivity of pharmaceutical age, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing the oral bioactivity of pharmaceutical age will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2055904